The PrIMAVeRa project announces the appointment of the Scientific Advisory Committee (SAC), a group comprised of international experts in epidemiology, vaccinology, public health, and antimicrobial resistance (AMR) research:
Alessandro Cassini: Deputy Cantonal Doctor of Vaud and the Infection Prevention and Control Unit of Lausanne University Hospital, Switzerland.
Mateusz Hasso-Agopsowicz: Technical Officer in Immunization, Vaccines and Biologicals at the World Health Organization.
Mical Paul: Head of the Infectious Diseases division of Rambam Health Care Campus and Professor at the Faculty of Medicine of Technion, Israel Institute of Technology.
Charlie Weller: Head of Prevention in the Infectious Diseases Area at Wellcome.
Mark Woolhouse: Professor of Infectious Disease Epidemiology at the University of Edinburgh.
If you would like to see more, kindly find bios of SAC members here
Project partners have already held two teleconferences with the SAC, sharing progress toward project goals and soliciting advice for current and future challenges, and members of the SAC also participated in the project’s first annual meeting in November 2022. In-depth scientific discussions have yielded valuable insights toward project activities aimed at contributing to the fight against AMR, with expert advice received on the topics of systematic reviews, potential additional sources of aggregate and individual-level data, methods for bridging gaps in existing datasets, and primary points of focus for ongoing efforts.
The PrIMAVeRa consortium expresses sincere gratitude to SAC members for their valuable input thus far. The SAC will maintain an active advisory role throughout the project, and partners are grateful for the further tangible benefits anticipated from their continued involvement and sharing of expertise.
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 101034420. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
This communication reflects the author´s view and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.